Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 620

Results For "RAT"

9503 News Found

AlloVir appoints Derek Adams to Board of Directors
People | February 27, 2023

AlloVir appoints Derek Adams to Board of Directors

Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.


Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData
Drug Approval | February 27, 2023

Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData

The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country


Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform
Biotech | February 27, 2023

Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.


Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
Drug Approval | February 25, 2023

Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine

This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


Pfizer’s Elranatamab receives FDA and EMA filing acceptance
Drug Approval | February 25, 2023

Pfizer’s Elranatamab receives FDA and EMA filing acceptance

Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma


MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates
Clinical Trials | February 24, 2023

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months